CASE SUMMARY

A 49-year-old gravida 3, para 2 premenopausal white female presented with subacute right mastalgia, erythema, and edema, plus palpable right axillary lymphadenopathy. Initial treatment with antibiotics provided no resolution. Further work-up, including bilateral diagnostic mammography and ultrasound, delineated diffuse skin thickening of the right breast and a 4-cm right axillary lymph node (new since screening mammogram 2 months prior). Ultrasound-guided core biopsy evinced infiltrating ductal carcinoma nuclear-grade 2 (ER +, PR -, HER-2/Neu -) within the lymphovascular spaces. Breast magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) scanning confirmed neither evidence of contralateral disease nor distant metastases, but showed hypermetabolic, enlarged supraclavicular lymphadenopathy (cT4dN3cM0, Stage IIIC). The patient completed 4 cycles of neoadjuvant adriamycin/cytoxan, followed by Taxotere and right modified-radical mastectomy, with complete pathologic response in the breast and 10 axillary lymph nodes. She completed adjuvant chest wall and supraclavicular radiotherapy to a dose of 50.4 Gy in 25 fractions, followed by a 10 Gy scar boost and a 5.4 Gy boost to the involved supraclavicular lymph node. The supraclavicular field was modified to incorporate the involved posterior-lateral supraclavicular lymph node (Figure 1). At last follow-up, there was no-evidence-of-disease at 8-months post-radiotherapy on adjuvant Tamoxifen without late complications.

IMAGING FINDINGS

Prechemotherapy PET/CT scans showed a 1.6-cm right posterior-lateral supraclavicular lymph node with a maximum SUV of 5.9, with complete metabolic response on postneoadjuvant chemotherapy PET/CT (Figure 2).

DIAGNOSIS

Clinical Stage IIIC (T4dN3cM0) inflammatory right breast cancer with complete metabolic and pathologic response to 4 cycles of neoadjuvant chemotherapy status following a right-modified radical mastectomy.

DISCUSSION

Numerous landmark randomized trials have established the importance of adjuvant locoregional radiotherapy in breast cancer, with a 1 in 4 reduction in breast cancer-specific survival for each locoregional recurrence prevented.1 Supraclavicular lymph-nodal irradiation is commonly incorporated into adjuvant radiotherapy, as supraclavicular failure accounts for 30% to 40% of locoregional recurrences following mastectomy and doxorubicin.
The emergence of CT-based planning and intensity-modulated radiation therapy (IMRT) has placed increased emphasis on accurate contouring of the clinical target volume (CTV) in lymph-node regions at risk for micrometastases in adjuvant breast radiotherapy. Current guidelines, such as The RTOG Contouring Atlas, serve as invaluable tools for the radiation oncology community; however, continued reassessment of appropriate target definitions and individualized patient application is essential.

Supraclavicular lymph node (SCLN) fields in breast cancer were formerly defined in 2-dimensional (2D) planning by the clavicular head, cricoid cartilage, cervical spine pedicle, and humeral head, which included the undissected level-III axillary region and low neck (level IV and adjacent level V) nodal regions (though coverage varied by depth). However, the definition for the SCLN CTV in 3-dimensional (3D) planning remains equivocal, but is of increasing importance. The current volumes recommended in The RTOG Contouring Atlas define the SCLN CTV to include the undissected axillary and level IV cervical lymph nodes. However, they omit the adjacent level V region, instead defining the SCLN borders as consisting of:

- Cranial: the cricoid cartilage;
- Caudal: the junction of the brachiocephalic and axillary veins clavicular head;
- Anterior: the sternocleidomastoid;
- Posterior: the anterior scalene muscle;
- Lateral: the sternocleidomastoid/clavicle-first rib junction; and,
- Medial: the thyroid and trachea.
Similarly, clinical trials, including the EORTC-22922 and MA-20 trials, have also focused on the medial SCLN. Studies quantifying SCLN recurrence have not separated medial from lateral SCLN.

With the emergence of PET/CT, both in locally advanced and inflammatory breast cancer, we increasingly have noted disease in posterior/lateral SCLN fossa (low neck level V). The presented IBC patient highlights one exemplary case (of at least 5 during a 3-year period) at our institution with SCLN extension into the lower neck nodes, which would not be included in the currently recommended RTOG contouring definitions (Figure 1). Others have reported similar concerns, where 15% of N3c patients had SCLN posterior to the transverse vertebral process, with level V representing 21% of the total SCLNs identified by PET/CT. Indiscriminate application of contouring guidelines without consideration for specific patient disease, anatomy, and risk could result in a geographic miss of posterior lateral SLCN, as seen Figure 3, where an infiltrating ductal carcinoma patient experienced isolated SCLN recurrence with posterior-lateral involvement.

**CONCLUSION**
The current definitions recommended in The RTOG Contouring Atlas may inadequately represent the lower, adjacent level V neck nodes, especially in patients with gross medial SCLN involvement and inflammatory or locally-advanced breast cancer at high-risk for subclinical disease. Caution is advised when applying this definition of the SCLN CTV in such patients without patient-specific consideration of disease, anatomy, and risk. Particular attention is warranted when using IMRT, where sharp dose gradients in the target area may increasingly omit at-risk nodal regions relative to 3D techniques. If available, pretreatment PET/CT should be focused carefully on identifying grossly involved posterior-lateral SCLN. Further research is warranted in defining patients who may benefit from including adjoining level V nodes. We recommend case-by-case consideration for individualized specification of medial-versus-lateral SCLN risk in applying current RTOG contouring guidelines to avoid geographic miss.

**REFERENCES**